CDH1 and familial pancreatic carcinoma: In agreement with our data, similar results on E-cadherin loss expression and translocation to the nucleus of β-catenin have been reported in breast and pancreatic cancer cells, and this is considered to be a marker of poor survival and resistance to therapies [24,49].